These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33713216)

  • 1. Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers.
    Hou MM; Ho CL; Lin HY; Zhu Y; Zhang X
    Invest New Drugs; 2021 Oct; 39(5):1315-1323. PubMed ID: 33713216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
    Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
    J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
    Denlinger CS; Keedy VL; Moyo V; MacBeath G; Shapiro GI
    Invest New Drugs; 2021 Dec; 39(6):1604-1612. PubMed ID: 34250553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
    Oh DY; Lee KW; Han SW; Kim JW; Shin JW; Jo SJ; Won J; Hahn S; Lee H; Kim WH; Bang YJ
    Oncologist; 2019 Aug; 24(8):1037-e636. PubMed ID: 31164456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
    Frentzas S; Kao S; Gao R; Zheng H; Rizwan A; Budha N; de la Hoz Pedroza L; Tan W; Meniawy T
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.
    Keam B; Ock CY; Kim TM; Oh DY; Kang WK; Park YH; Lee J; Lee JH; Ahn YH; Kim HJ; Chang SK; Park J; Choi JY; Song YJ; Park YS
    Invest New Drugs; 2021 Dec; 39(6):1624-1632. PubMed ID: 34268711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
    Cleary JM; Calvo E; Moreno V; Juric D; Shapiro GI; Vanderwal CA; Hu B; Gifford M; Barch D; Roberts-Rapp L; Ansell PJ; Xiong H; Ocampo C; Tolcher AW
    Invest New Drugs; 2020 Oct; 38(5):1483-1494. PubMed ID: 32189093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
    Kollmannsberger C; Britten CD; Olszanski AJ; Walker JA; Zang W; Willard MD; Radtke DB; Farrington DL; Bell-McGuinn KM; Patnaik A
    Invest New Drugs; 2021 Dec; 39(6):1613-1623. PubMed ID: 34264412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
    Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
    Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
    de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
    Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors.
    Doi T; Aramaki T; Yasui H; Muro K; Ikeda M; Okusaka T; Inaba Y; Nakai K; Ikezawa H; Nakajima R
    Invest New Drugs; 2019 Oct; 37(5):1061-1074. PubMed ID: 30623276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.
    You B; Brade A; Magalhaes JM; Siu LL; Oza A; Lovell S; Wang L; Hedley DW; Nicacio LV; Chen EX
    Invest New Drugs; 2011 Oct; 29(5):996-1003. PubMed ID: 20454832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial.
    Zhu X; Ding Y; Wang Q; Yang G; Zhou L; Wang Q
    Invest New Drugs; 2023 Jun; 41(3):473-482. PubMed ID: 37140695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
    Hartmann JT; Kollmannsberger C; Cascorbi I; Mayer F; Schittenhelm MM; Heeger S; Bokemeyer C
    Invest New Drugs; 2013 Jun; 31(3):661-8. PubMed ID: 22832803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
    Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
    Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.